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AbstrAct
ObjeCtive
To evaluate whether a disease activity guided strategy 
of dose reduction of two tumour necrosis factor (TNF) 
inhibitors, adalimumab or etanercept, is non-inferior 
in maintaining disease control in patients with 
rheumatoid arthritis compared with usual care.
Design
Randomised controlled, open label, non-inferiority 
strategy trial.
setting
Two rheumatology outpatient clinics in the 
Netherlands, from December 2011 to May 2014.
PartiCiPants
180 patients with rheumatoid arthritis and low disease 
activity using adalimumab or etanercept; 121 allocated 
to the dose reduction strategy, 59 to usual care.
interventiOns
Disease activity guided dose reduction (advice to 
stepwise increase the injection interval every three 
months, until flare of disease activity or 
discontinuation) or usual care (no dose reduction 
advice). Flare was defined as increase in DAS28-CRP 
(a composite score measuring disease activity) greater 
than 1.2, or increase greater than 0.6 and current score 
of at least 3.2. In the case of flare, TNF inhibitor use 
was restarted or escalated.
Main OutCOMe Measures
Difference in proportions of patients with major flare 
(DAS28-CRP based flare longer than three months) 
between the two groups at 18 months, compared 
against a non-inferiority margin of 20%. Secondary 
outcomes included TNF inhibitor use at study end, 
functioning, quality of life, radiographic progression, 
and adverse events.
results
Dose reduction of adalimumab or etanercept was 
non-inferior to usual care (proportion of patients with 
major flare at 18 months, 12% v 10%; difference 2%, 
95% confidence interval −12% to 12%). In the dose 
reduction group, TNF inhibitor use could successfully 
be stopped in 20% (95% confidence interval 13% to 
28%), the injection interval successfully increased in 
43% (34% to 53%), but no dose reduction was 
possible in 37% (28% to 46%). Functional status, 
quality of life, relevant radiographic progression, and 
adverse events did not differ between the groups, 
although short lived flares (73% v 27%) and minimal 
radiographic progression (32% v 15%) were more 
frequent in dose reduction than usual care.
COnClusiOns
A disease activity guided, dose reduction strategy of 
adalimumab or etanercept to treat rheumatoid arthritis 
is non-inferior to usual care with regard to major 
flaring, while resulting in the successful dose 
reduction or stopping in two thirds of patients.
trial registratiOn
Dutch trial register (www.trialregister.nl), NTR 3216.
Introduction
Tumour necrosis factor (TNF) inhibitors are effective in 
the treatment of rheumatoid arthritis, improving clini-
cal, functional, and radiographic outcomes.1 2 Different 
TNF inhibitors are widely used, with adalimumab 
(40 mg every two weeks) and etanercept (50 mg every 
week or 25 mg twice a week) being the most used,3 and 
among the highest selling drugs worldwide.4
Treatment with TNF inhibitors is not without its 
drawbacks: they are associated with (dose depen-
dent) adverse effects, including increased risk of 
infections and skin cancer.5–7 Furthermore, such treat-
ment is costly, at about €14 000 per year per patient.8 
Optimising the use of TNF inhibitors is therefore 
 warranted. Previous research has suggested that dose 
reduction or discontinuation of these inhibitors 
WhAt Is AlreAdy knoWn on thIs topIc
Tumour necrosis factor (TNF) inhibitors adalimumab and etanercept are effective in 
rheumatoid arthritis, but are associated with some side effects and high costs
Dose reduction or stopping (tapering) of TNF inhibitor use is feasible in many 
patients, although it cannot be predicted which patient can be tapered
In general, disease activity guided strategies to treat rheumatoid arthritis have 
resulted in optimal clinical outcomes
WhAt thIs study Adds
A treat-to-target based TNF inhibitor tapering strategy, consisting of increases in 
intervals between injections until the patient flares or the drug can be stopped, is 
non-inferior to usual care (a treat-to-target strategy without dose reduction), with 
regard to occurrence of major flare 
Although short lived flares and minimal radiographic progression occurred more 
frequently with dose reduction, it showed similar outcomes to usual care after 18 
months for functioning, quality of life, adverse events, and clinically relevant 
radiological joint damage
Dose reduction or stopping was successful in two third of patients
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 without the deterioration of disease activity is possi-
ble in a relevant proportion of patients, although suc-
cessful dose reduction cannot be predicted in 
individual patients.9–11 Therefore, a promising strat-
egy might be to slowly taper the use of TNF inhibitors 
until it is stopped, while carefully monitoring the dis-
ease, and increase the dose or restart when necessary. 
However, some important questions regarding the 
feasibility and applicability of dose reduction in indi-
vidual patients in clinical practice remain unan-
swered. For example, it is not known whether a 
disease activity guided strategy—that is, a strategy of 
monitoring the disease activity and restarting the use 
of TNF inhibitors or increasing the dose again if the 
disease worsens after dose reduction—results in care 
that is equally as good as just continuing treatment 
unaltered. Flares in disease activity that occur after 
dose reduction might be (1) short lived and easily 
treated or (2) prolonged, compromising quality of life 
or resulting in radiological damage.12 Also, although 
titration to the lowest dose might save treatment 
costs, it could also lead to an increased number of 
patient contacts and consequent costs. Interestingly, 
none of the previous controlled dose reduction and 
discontinuation studies used the appropriate non-in-
feriority design, included a disease activity guided 
strategy, or reported cost effectiveness analyses.9–11
Therefore, this study aimed to demonstrate non- 
inferiority with regard to efficacy and safety between a 
disease activity guided strategy of dose reduction in 
TNF inhibitors and usual care (that is, continuing TNF 
inhibitor use), in daily clinical practice for patients with 
rheumatoid arthritis. We also planned to assess the 
 possible benefits of decreasing TNF inhibitor use. 
A  secondary aim was to identify possible predictors for 
successful dose reduction.
Methods
study design and participants
The Dose REduction Strategy of Subcutaneous TNF 
inhibitors (DRESS) study was a pragmatic, open label, 
randomised controlled, non-inferiority trial, stratified by 
the TNF inhibitor used. The rationale and design have 
been described extensively elsewhere,13 and are sum-
marised here. We enrolled consenting patients with 
rheumatoid arthritis (based on 2010 or 1987 American 
College of Rheumatology criteria, or clinical diagnosis by 
the treating rheumatologist) using adalimumab or 
etanercept at any stable dose and interval for at least six 
months, with stable low disease activity at two subse-
quent visits. Low disease activity was determined by the 
rheumatologist and measured using the DAS28-CRP 
score. This validated composite score measures disease 
activity (range 0.9–9) and includes 28 swollen and tender 
joint counts, patients’ judgment of global disease activ-
ity, and C reactive protein level. The study was performed 
at the Sint Maartenskliniek in Nijmegen and Woerden, 
the Netherlands, from December 2011 to May 2014, and 
was approved by the local ethics committee (Commissie 
Mensgebonden Onderzoek region Arnhem-Nijmegen, 
NL37704.091.11). The study was registered with the Dutch 
trial register (www.trialregister.nl, NTR 3216) one week 
after study inclusion started, owing to temporary inca-
pacitation of the research doctor.
randomisation and masking
Allocation was stratified by TNF inhibitor using block 
randomisation in random sized blocks (block size 3–12), 
and in a ratio of dose reduction versus usual care of 2:1. 
This ratio was chosen to include more determinants in 
a prediction model for successful dose reduction or dis-
continuation. A research physician allocated patients 
using a randomisation list generated by computer. To 
conceal the sequence until treatment strategy was 
assigned, sequentially numbered sealed opaque enve-
lopes that contained the randomly assigned allocations 
were used.
Procedures
Patients allocated to the usual care group continued a 
standardised treat-to-target treatment protocol, aimed 
at maintaining at least low disease activity. Visits were 
planned every three months and patients were encour-
aged to contact the outpatient clinic if they experienced 
more symptoms. DAS28-CRP scores were assessed by 
nurses and provided to the treating rheumatologists. 
Nurses had been trained and their joint assessment 
skills were calibrated repeatedly to optimise inter-rater 
reliability. Treatment was changed in case of a disease 
activity flare. We defined a flare using a validated crite-
rion: an increase in DAS28-CRP score of more than 1.2, 
or a score increase of more than 0.6 compared with 
baseline score, where the current score was at least 
3.2.14 If a flare occurred, a new visit after four weeks was 
advised. Intramuscular and intra-articular glucocorti-
coid injections were allowed.
In the dose reduction group, patients received identi-
cal care as the usual care group, with addition of a dose 
reduction advice given for that particular patient to the 
treating rheumatologist. The dose reduction strategy 
consisted of stepwise increases of the time interval 
between injections every three months. For adalim-
umab, the steps were (1) 40 mg every 21 days, (2) 40 mg 
every 28 days, and (3) stop. For etanercept, the steps 
were (1) 50 mg every 10 days, (2) 50 mg every 14 days, 
and (3) stop. In the instance of a flare, the last effective 
interval was reinstated; if the flare persisted, TNF inhib-
itor use was increased up to the shortest registered 
interval, and treatment was switched thereafter in case 
of persisting flare. Only one attempt at dose reduction 
was done, and in the case of flare and treatment escala-
tion, no further attempts at reduction were made.
Outcomes
Primary outcome was the difference in cumulative inci-
dence of major flare between the dose reduction and 
usual care groups at 18 month follow-up.13 Major flare 
was defined as a DAS28-CRP based flare with a duration 
of longer than three months, independent of treatment 
changes.13 We initially planned the primary outcome to 
be the cumulative incidence of all flares (now a second-
ary outcome). The reason for the switch of primary 
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 outcome was the developing insight that transient flar-
ing is an inherent trait of all dose tapering strategies 
based on disease activity. However, when a flare can be 
treated easily, and does not lead to loss of function, 
quality of life, persistent increase of disease activity, 
increase of other treatment, clinically relevant radio-
graphic damage, and prolonged major flare, in our view 
this can be reasonably viewed as non-inferior care. The 
outcome change took place after study start but before 
outcomes were available, as has been published else-
where.13 Patients with major flare were reviewed further 
by two doctors.
Secondary outcomes included cumulative incidence 
of patients with short lived flare (duration >three 
months); change in DAS28-CRP score; change in func-
tioning, as measured by the health assessment ques-
tionnaire-disability index (HAQ-DI; range 0–3, higher 
score indicating worse functioning); and quality of life, 
as measured by EuroQol-5D-5L (EQ5D-5L; range 0–1, 
higher score indicating better quality of life). These out-
comes were assessed at nine and 18 months’ follow-up. 
We recorded the proportions of patients who could suc-
cessfully taper or stop treatment, as well as any change 
in the use of glucocorticoids or disease modifying anti-
rheumatic drugs (DMARDs), and the occurrence of 
severe adverse events.
Radiographs of hands and feet (at baseline and 18 
months) were assessed in chronological order by two 
blinded, trained readers, using the modified Sharp-van 
der Heijde (SvdH) score (range 0–448; higher scores 
indicate more joint damage). These values included 
subscores for erosion (range 0–280) and joint space 
narrowing (range 0–168).15 The proportion of patients 
with a change in SvdH score exceeding the minimal 
clinical important change of eight points in 18 months 
was compared between groups.16 17 As a sensitivity anal-
ysis, the smallest detectable change was calculated and 
used as cut-off value, as well as a third cut-off value of 
0.5 SvdH units.18 We calculated quality adjusted life 
years based on EQ5D-5L scores to analyse quality of life 
differences.
We also assessed costs, cost effectiveness, and the 
predictive value of serum drug levels and whole body 
PET/CT scanning (positron emission tomography com-
bined with computed tomography) scans. These results 
will be published in separate publications.
statistical analysis
We assumed that 20% of patients would experience the 
primary outcome in the dose reduction arm and 15% in 
the usual care arm. With one sided testing (α=0.05, 
1−β=0.8), a non-inferiority margin of 20%, and rando-
misation ratio of 2:1 dose reduction versus usual care 
and accounting for 5% dropout, we calculated that 180 
patients would be necessary to reject the null hypothe-
sis of inferiority.13 No interim analyses or stopping rules 
were defined before study start.
The chosen non-inferiority margin is to some extent 
arbitrary, because no non-inferiority studies on rheu-
matoid arthritis have used major flare as outcome. How-
ever, in our opinion, a difference in persistent flare of 
over 20% between the usual care and dose reduction 
groups would constitute a clinically relevant non- 
inferiority margin. The underlying reasoning is that 
half of patients who start another biologic to treat a 
flare are expected to show a response again within three 
months.1 2 Therefore, half of 20% of the patients would 
experience a persistent flare—that is, a more prolonged 
period with uncontrolled disease activity—resulting in 
a number needed to harm of 10. In our clinical view, this 
number seems to balance well with an expected chance 
of being able to reduce the dose or stop the drug of 
about 60% and 15% respectively (numbers need to treat 
1.5 and 6, respectively), because many more patients are 
expected to benefit than be harmed using this non-infe-
riority margin.
Primary analyses were done per protocol by includ-
ing only patients who (1) completed follow-up, (2) actu-
ally started dose reduction of TNF inhibitors in the dose 
reduction arm, and (3) had not stopped or reduced TNF 
inhibitor use at 18 months’ follow-up in the usual care 
arm. Additional intention to treat analyses were also 
done. For the primary outcome, we calculated the point 
estimate and confidence interval of the difference in 
cumulative incidence of major flare between both 
groups, and compared the upper limit of the confidence 
interval with the non-inferiority margin. A t test com-
pared mean values (and mean time averaged) for 
DAS28-CRP, HAQ-DI, and EQ5D-5L. We used the χ2 test 
to analyse the difference in cumulative incidence of 
flares, and the levels of disease activity at baseline, nine 
months, and 18 months. The different timepoints were 
tested separately, with no repeated measure analyses 
performed.
To identify predictors, we performed two univariate 
logistic regression analyses. The two main outcomes—
successful dose reduction and stopping—were depen-
dent variables, and patient, clinical, and treatment 
variables at baseline were independent variables. We 
planned multivariate analyses in case more than one 
variable was significantly associated with one of the 
outcomes.
results
Patients
We enrolled 180 patients, 121 in the intervention group 
and 59 in the usual care group (fig 1). Baseline charac-
teristics were similar between the two groups, except 
for higher prevalence of DMARD cotreatment in the 
usual care group (table 1). Almost no data were missing 
(2% of the planned visits, and 3–7% missing per vari-
able); thus multiple imputation was deemed unneces-
sary. There were no differences in missing levels by 
randomisation group.
Primary outcome, disease activity, function, and 
quality of life outcomes
Using the primary per protocol analysis (fig 1 for num-
bers and reasons for excluded patients), the cumulative 
incidence of major DAS28-CRP flare was 14 (12%) of 119 
patients in the dose reduction group and five (10%) of 
50 patients in the usual care group. The upper limit of 
 o
n
 13 O
ctober 2019 at Radboud University Nijmegen. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.h1389 on 9 April 2015. Downloaded from 
RESEARCH
4 doi: 10.1136/bmj.h1389 | BMJ 2015;350:h1389 | the bmj
the 95% confidence interval around the difference was 
lower than the non-inferiority margin of 20% (2%, 95% 
confidence interval −12% to 12%), showing that the dose 
reduction strategy was non-inferior to usual care. Addi-
tional intention to treat analyses showed similar results 
(fig 2). We found no relevant between drug differences 
in the stratified analysis. Therefore, all further analyses 
were done according to intention to treat. The cumula-
tive incidence of major flare at nine months was seven 
(6%) of 121 patients in the dose reduction group and 
two (3%) of 59 patients in the usual care group. In-depth 
clinical review of all intention to treat patients with 
major flare (n=21) showed three clinically distinct sub-
groups. The first group (n=8) showed no flare clinically, 
but fulfilled the formal flare criterion due to spuriously 
high C reactive protein, incident comorbidity, or social 
context (for example, psychosocial stress). The second 
group had a clinical flare, but treatment was subopti-
mal owing to, for example, adverse events or the 
patient’s wishes (n=8). The third group also had clinical 
flare, but showed no improvement after optimal treat-
ment including reinstallment of  previous TNF inhibitor 
treatment (n=5, of whom four patients were in the dose 
reduction group).
The cumulative incidence of short lived flares was 
significantly higher in the dose reduction group than 
the usual care group (66/121 patients (55%, 95% confi-
dence interval 45% to 64%) v 12/59 (20%, 11% to 33%) at 
nine months’ follow-up; 88 (73%, 64% to 80%) v 16 
(27%, 17% to 40%) at 18 months’ follow-up (both 
P<0.001)). Figure 3 shows the number of flares per 
patient with at least one flare during the study. Mean 
DAS28-CRP scores remained low in both groups, with a 
temporary small but significant increase in the dose 
reduction group at nine months (fig 4A), also resulting 
in a higher mean time averaged DAS28-CRP in this 
group (P<0.01). Table 2 shows proportions of patients 
with DAS28CRP scores below 3.2, 2.6, or in remission 
(according to 2011 American College of Rheumatology/
European League Against Rheumatism Boolean based 
criteria). Mean (time averaged) functioning and quality 
of life remained stable and did not differ significantly 
between the two groups (figs 4B and 4C).
treatment and prediction modelling
In the dose reduction group (n=121), TNF inhibitor use 
at 18 months was successfully discontinued in 24 
patients (20%, 95% confidence interval 13% to 28%) 
and tapered in 52 (43%, 34% to 53%). No dose reduction 
was possible in 45 patients (37%, 28% to 46%). For 
patients using adalimumab at 18 months, 26% and 36% 
had successfully discontinued or tapered inhibitor use, 
and 38% could not reduce the dose; corresponding pro-
portions for etanercept at 18 months were 17%, 47%, 
and 36%.
In the usual care group (n=59), four patients (7%, 
95% confidence interval 2% to 17%) discontinued TNF 
inhibitor use (all because of adverse effects), five (8%, 
3% to 19%) tapered use because of low disease activity, 
and 50 patients did not reduce inhibitor dose (85%, 73% 
to 92%). At 18 months, four (3%) of 121 patients in the 
dose reduction group were switched to another drug, 
compared with four (7%) of 59 in the usual care group.
All characteristics in table 1 were tested for their pre-
dictive value. No clinical, laboratory, or cotreatment 
variables were significantly associated with successful 
dose reduction or discontinuation of TNF inhibitor 
treatment.
Intramusclar or intra-articular glucocorticoid injec-
tions were given to 43 patients (36%, 95% confidence 
interval 27% to 45%) in the dose reduction group 
(n=121) and 14 (24%, 14% to 37%) in the usual care 
group (n=59, P=0.26). Figure 5 shows the number of 
injections per patient for those receiving parenteral glu-
cocorticoids on at least at one occasion. At 18 months, 
eight (7%, 3% to 13%) and six (10%, 4% to 22%) patients 
in the dose reduction and usual care groups, respec-
tively, used oral glucocorticoids (P=0.56). DMARDs were 
reduced or discontinued more often in the usual care 
group than in the dose reduction group (16 (27%, 17% to 
40%) v 12 (10%, 5% to 17%); P<0.01), while DMARD ini-
tiation or dose escalation occurred more often in the 
dose reduction group than in the usual care group (16 
(13%, 8% to 21%) v 2 (3%, 6% to 13%); P<0.05). At 18 
months, the percentage of patients using a DMARD 
remained lower in the dose reduction group (74 (61%, 
52% to 70%)) than in the usual care group (41 (69%, 
56% to 80%); P=0.61).
radiological outcomes and safety
Radiographs were available for 175 patients (table 3). 
In neither group did any of the patients have a SvdH 
 progression score exceeding the minimal clinical import-
ant change of eight points. The sensitivity analyses showed 
Assessed for eligibility (n=734)
Randomised (n=180)
Allocated to dose reduction strategy (n=121):
  Etanercept (n=79)
  Adalimumab (n=42)
Received dose reduction strategy (n=121) Received usual care (n=59)
Intention to treat analyses at 18 months’
  follow-up (n=121):
    Per protocol analyses at 18 months'
      follow-up (n=119)
    Participants excluded (n=2)
      Lost to follow-up (n=2)
Intention to treat analyses at 18 months’
  follow-up (n=59):
    Per protocol analyses at 18 months'
      follow-up (n=50)
    Participants excluded (n=9)
      TNFI dose reduction (n=5)
      TNFI discontinuation (n=4)
Allocated to usual care (n=59):
  Etanercept (n=39)
  Adalimumab (n=20)
Did not start dose reduction (n=0)
Lost to follow-up (n=0)Lost to follow-up (n=2):
  Withdrew consent (n=1)
  Moved (n=1)
Excluded (n=544):
  Not meeting inclusion criteria at prescreening (n=332)
    No low disease activity
    Period low disease activity too short
    Change in (co)treatment
  Declined to participate or not meeting inclusion criteria at screening (n=222)
Fig 1 | Flowchart of patient recruitment and dropout. tnFi=tnF inhibitor
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no difference when using the smallest detectable change 
(4.1 points) as a cut-off value. More patients in the dose 
reduction arm exceeded the 0.5 units progression than in 
the usual care arm (fig 6). The difference in mean pro-
gression between groups was small but significant and 
was mainly due to difference in joint space narrowing, 
because progression in erosion scores was similar.
The occurrence of adverse events was similar 
between the groups (table 4). The, non-significant, 
higher incidence of overall serious adverse events was 
caused by more elective surgeries (mostly orthopaedic). 
Frequency of serious infections, cardiovascular events, 
and malignancies was similar between groups.
discussion
To our knowledge, this is the first study to show that a 
disease activity guided dose reduction strategy of adali-
mumab or etanercept in patients with rheumatoid 
table 1 | baseline patient characteristics
Dose reduction  
(n=121)
usual care  
(n=59)
general characteristics
Age (years)* 59 (10.5) 58 (9.3)
Female sex 75 (62) 41 (69)
Current smoking 29 (24) 18 (31)
Body mass index* 27 (4.9) 26 (4.0)
Diagnosis according to 2010 or 1987 ACR criteria 114 (94) 58 (98)
Disease duration (years)† 10 (6–17) 10 (6–16)
Rheumatoid factor positive 94 (78) 49 (83)
Anti-citrullinated peptide antibodies positive 77 (64) 39 (68)
Erosive disease 99/116 (85) 54 (92)
SvdH score† 23 (6–50) 17.5 (8.5–46.5)
Employed 44 (36) 21 (36)
Travel distance (one way) to hospital (km)† 30.4 (13.5–47.2) 33.2 (17.3–50)
Disease activity
No of swollen joints† 0 (0–0) 0 (0–1)
No of tender joints† 0 (0–1) 0 (0–0)
Erythrocyte sedimentation rate (mm/h)* 17 (14) 16 (10)
C reactive protein (mg/L)* 4 (4) 4 (4)
DAS28-CRP score* 2.2 (0.6) 2.1 (0.7)
DAS28-ESR score* 2.5 (0.7) 2.5 (0.8)
2011 ACR/EULAR Boolean based remission 31 (26) 21 (36)
treatment
Etanercept/adalimumab 79/42 (65/35) 39/20 (66/34)
Duration of current TNF inhibitor treatment (years)* 3.5 (2.5) 3.6 (2.3)
Previous dose reduction attempt with current TNFi 21 (17) 11 (19)
Previous DMARD treatment† 2 (1–3) 2 (1–3)
Previous conventional synthetic DMARD combination 
treatment‡
30/100 (30) 22/49 (45)
Previous TNF inhibitor treatment† 0 (0–1) 0 (0–1)
Concomitant treatment
 DMARD 73 (60) 47 (80)
 Methotrexate 58 (48) 41 (69)
 Methotrexate dose (mg)* 15.8 (5.7) 16.1 (5.5)
 Glucocorticoids 6 (5) 3 (5)
 Non-steroidal anti inflammatory drugs 65 (54) 35 (59)
Data are number (%) of patients unless stated otherwise. ACR/EULAR=American College of Rheumatology/
European League Against Rheumatism.
*Mean (standard deviation).
†Median (interquartile range).
‡In the dose reduction and usual care groups, 21 and 10 patients had missing values, respectively.
Per protocol analyses, whole group
Intention to treat analyses, whole group
Per protocol analyses, adalimumab
Per protocol analyses, etanercept
-30-40 -20 -10 0 10 20
Non-inferiority margin
30 40
Favours dose reduction Favours continuation
Fig 2 | Primary outcome analyses
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Fig 3 | numbers of flares per patient during the study
A
B
C
Months
M
ea
n 
DA
S2
8-
CR
P 
(d
is
ea
se
 a
ct
iv
ity
)
0
2
3
4
5
6
1
0 3 6 9 12 15 18
M
ea
n 
HA
Q-
DI
 (f
un
ct
io
ni
ng
)
0
1.0
1.5
2.0
2.5
3.0
0.5
M
ea
n 
EQ
5D
-5
L (
qu
al
ity
 o
f l
ife
)
0
0.4
0.6
0.8
1.0
1.2
0.2
Dose reduction
Usual care
3.2
2.6
Fig 4 | Mean scores for (a) disease activity, (b) functioning, 
and (C) quality of life during planned study visits for the 
dose reduction and usual care groups
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arthritis and doing well is non-inferior to usual care for 
occurrence of major flare, while resulting in successful 
dose reduction or stopping in two third of the patients. 
In the majority of patients, TNF inhibitor intervals could 
be increased or TNF inhibitors could be discontinued 
without a difference in major flares, disease activity 
after 18 months, functioning, clinically relevant radio-
graphic progression, quality of life, side effects, or other 
treatment between the dose reduction strategy and 
usual care. However, short lived flares and minimal 
radiographic progression were more frequent in the 
dose reduction group. No predictive factors for success-
ful dose reduction or discontinuation could be found.
strengths and limitations of study
The internal validity of our study was strengthened by 
the randomised design, use of validated outcome mea-
sures, and comparable treatment strategy in both arms, 
with the exception of the dose reduction advice. The 
number of patients needed according to our sample size 
calculation was met and loss to follow-up and missing 
data were kept to a minimum.
Some methodological choices that our study was 
based on can be challenged. Firstly, the prespecified 
non-inferiority margin we chose was to some extent 
arbitrary, because only four non-inferiority studies so 
far have focused on the use of DMARD or biologicals in 
rheumatoid arthritis, and none was a strategy study or 
had used flare as a primary outcome. Our non-inferiority 
margin was considered clinically reasonable, because 
the resulting minimum number needed to harm of one 
in 10 (that is, a 10% difference between groups in major 
flare) seemed a fair trade-off when considering that the 
expected number needed to benefit was lower than one 
in two (that is, 50% difference between groups in suc-
cessful dose reduction or stopping).
Furthermore, this study was not blinded. However, 
any potential expectation bias would lean towards the 
overestimation of short lived flares and the parallel 
underestimation of proportion of patients who can suc-
cessfully taper in the intervention group, because both 
patients and doctors would expect a high risk of flare. 
This expectation is contrary to regular randomised con-
trolled trials in which treatment is started, because in 
these trials, expectation of response can lead to inflated 
measures for effectiveness. A blinded study would thus 
probably have resulted in the same estimates with 
regard to major flares (no difference), lower incidence of 
short lived flares, and higher proportion of patients 
with successfully tapered treatment. This notion is sup-
ported by data from the PRESERVE study, which 
showed a higher percentage of patients who could 
reduce dose and stop treatment than in our study.9 
Also, whether we chose the best flare criterion can be 
debated. Several non-validated flare criteria have been 
used in dose reduction and discontinuation research.19 
Our DAS28 based flare criterion has been validated, 
 correlating well with patient and doctor judgment of 
disease worsening, and showing good construct valid-
ity. However, the optimal definition of flare is still under 
debate, with work currently in progress to develop 
patient reported flare criteria.20
Some differences in baseline characteristics and 
treatment during follow-up between the dose reduction 
and usual care groups could have resulted in bias. For 
example, lack of DMARD cotreatment and a higher level 
of radiological damage at baseline were more prevalent 
in the dose reduction group than the usual care group. 
However, these differences would have caused bias in 
the conservative direction, as they seem to favour the 
usual care group. This baseline imbalance in DMARD 
use is probably a reason for DMARDs being more often 
escalated or initiated in the dose reduction group, while 
dose reduction and discontinuation of DMARDs was 
more frequent in the usual care group. Furthermore, 
table 2 | Disease activity levels at baseline and nine and 18 month follow-up
Dose reduction 
(n=121)
usual care 
(n=59) P*
Baseline
 DAS28-CRP score <3.2 113 (93) 53 (90) —
 DAS28-CRP score <2.6 92 (76) 48 (81) —
 2011 ACR/EULAR Boolean based remission 31 (26) 21 (36) —
9 month follow-up
 DAS28-CRP score <3.2 89 (74) 54 (92) 0.005
 DAS28-CRP score <2.6 73 (60) 48 (81) 0.005
 2011 ACR/EULAR Boolean based remission 22 (18) 17 (29) 0.104
18 month follow-up
 DAS28-CRP score <3.2 103 (85) 53 (90) 0.464
 DAS28-CRP score <2.6 86 (71) 47 (80) 0.218
 2011 ACR/EULAR Boolean based remission 29 (24) 24 (41) 0.021
Data are number (%) of patients. ACR/EULAR=American College of Rheumatology/European League Against 
Rheumatism.
*χ2, crude estimates without adjustments.
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some patients in the usual care group wished to reduce 
the dose of other drugs, because TNF inhibitor treat-
ment was aimed to remain stable. However, use of 
DMARDs and oral glucocorticoids at the end of the 
study was still more prevalent in the usual care group. 
We therefore think that these between group differences 
do not invalidate our conclusions of non-inferiority 
with regard to the clinical outcome and much lower 
TNF inhibitor use.
Although not statistically significant, the number of 
severe adverse events was higher in the dose reduction 
group than in the usual care group. This difference 
was, however, mostly caused by higher occurrence of 
elective surgery (joint replacement, arthrodesis, and 
joint prosthesis revision). A possible reason for this 
could be that surgeons are more likely to operate when 
patients are using a lower dose of TNF inhibitors or 
none at all. Also, as part of a substudy, whole body 
PET/CT scans were performed in the dose reduction 
group, revealing abnormal results in four patients, who 
then needed surgery. Because no PET/CT scans were 
performed in the usual care group, this result seems a 
case of information bias.
Comparison with other studies
How should our study results be interpreted in the light 
of existing evidence on tapering and stopping TNF 
inhibitor use? There are several studies on dose reduc-
tion and discontinuation of TNF inhibitors. However, 
most have been small, uncontrolled, and heteroge-
neous in design and outcomes, or compare fixed dose 
reduction or discontinuation without the possibility to 
increase the dose, which makes it difficult to compare 
results.11
When considering disease activity guided tapering in 
an individual patient, it is important to interpret and 
weigh the increased occurrence of short lived flares, 
their treatment, and the increased risk of minimal 
radiographic progression against reduced TNF inhibitor 
exposition and its advantages. In our view, the clinical 
effect of these short lived flares and their treatment is 
limited, and in general seems worth the trade-off with 
much lower TNF inhibitor exposition, including fewer 
injections and probably a lower risk for long term side 
effects. However, the perceived risk-benefit balance can 
differ between patients and also doctors, and shared 
decision making is therefore important in this context.
The difference in minimal radiological progression 
can be interpreted in several ways. It might have been 
caused by the one time, short lived flares that were more 
frequent in the dose reduction arm than in the usual 
care arm. In this case, it is to be expected that when 
treatment is not changed in future years, progression 
will be similar between both groups, and the difference 
remains clinically irrelevant. An alternative hypothesis 
is that the difference in progression is caused by lower 
TNF inhibitor exposition itself, and in this scenario, 
between group differences could become clinically rel-
evant after, for example, a decade. A long term ongoing 
extension study is currently being performed to answer 
these questions.
Conclusions and policy implications
We have shown the non-inferiority of a feasible dose 
reduction strategy of adalimumab or etanercept com-
pared with usual care for occurrence of major flare in 
patients with rheumatoid arthritis and low disease 
activity. Implementation of this strategy would proba-
bly vastly improve the cost effectiveness of rheumatoid 
arthritis treatment, although formal cost effectiveness 
analyses should confirm this first. An important aspect 
of generalisability of our dose reduction strategy was its 
treat-to-target protocol (that is, aiming to maintain at 
least low disease activity). This aspect is important in 
the treatment of rheumatoid arthritis,21 22 but especially 
so when disease activity guided dose reduction is 
attempted due to the increased risk of flare. In this 
study, implementation of the treat-to-target protocol 
was satisfactory, as witnessed by the low DAS28-CRP 
scores during the study in both groups. However, imple-
mentation of this strategy on a large scale and in other 
healthcare systems and countries could be challenging, 
for example, owing to potentially long travel distances 
for patients.23 24
Future research should include longer follow-up 
studies confirming persistence of non-inferiority for 
clinical and radiographic outcomes and assessing pos-
sible superiority for adverse events. Other potential 
table 3 | radiographic outcomes (n=175)
Dose reduction 
(n=116)
usual care 
 (n=59)
Difference  
(95% Ci)
Progression total SvdH score* 0.75 (1.5) 0.15 (1.1) 0.60 (0.17 to 1.0)
Progression erosion score* 0.29 (0.8) 0.12 (0.7) 0.17 (−0.07 to 0.41)
Progression joint space narrowing* 0.46 (1.2) 0.03 (0.9) 0.43 (0.08 to 0.78)
Progression >minimal clinical 
important change (8 units)†
0 0 0% (−8% to 4%)
Progression >smallest detectable 
change (4.1 units)†
5 (4%) 0 4% (−4% to 10%)
Progression >0.5 units† 37 (32%) 9 (15%) 17% (2% to 29%)
Progression=in units per 18 months.
*Mean (standard deviation).
†Number (%) of patients.
table 4 | safety summary
Dose reduction (n=121) usual care (n=59) Difference (95%Ci)
Flares
All flares 88 (73) 16 (27) 46% (30% to 58%)
Major flares 15 (12) 6 (10) 2% (−9% to 11%)
Other adverse events
Adverse events 95 (79) 45 (76) 2% (−9% to 16%)
Serious adverse events* 30 (25) 7 (12) 13% (−1% to 24%)
Planned surgery 11 (9) 1 (2) 7% (−1% to 14%)
PET/CT scan related† 4 (3) — —
Cardiovascular event 5 (4) 1 (2) 2% (−5% to 8%)
Infectious adverse event 3 (2) 3 (5) −3% (−12% to 3%)
Malignancy 6 (5) 2 (3) 2% (−7% to 8%)
Allergic (injection) reaction 0 0 0
Death 0 0 0
Data are no (%) of patients. Cumulative incidence at 18 months: no of patients with at least one event in the study 
period. PET/CT=positron emission tomography/computed tomography.
*Four patients (all in the dose reduction group) had two serious adverse events each.
†Patients allocated to the dose reduction group were asked for a substudy, which included a whole body PET/CT 
scan. Four patients were diagnosed with extra-articular abnormalities that needed explorative surgery.
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 predictors for successful dose reduction and discontin-
uation (biomarkers, ultrasound, PET/CT) could be 
investigated to further minimise the risk of flaring.
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